SJF 1528 - ≥98%(HPLC) , CAS No.2230821-38-0

CAS: 2230821-38-0 Cat. No.: S287968 Formula: C55H57ClFN7O8S Peso molecolare: 1030.61 PubChem CID: 135157151
Disponibile su ordine
QUALITÀ & PUREZZA ≥98%(HPLC)
Synonyms
(2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6- yl)phenoxy)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Storage
Store at -20°C
Shipped In
Ice chest + Ice pads
★
Dimensione
Germania (EU)
USA*
Prezzo
Qtà
5mg
S287968-5mg
Su ordinazione · 8–12 settimane
616,88€
Enter a quantity for the sizes you want to add.

Specifiche

Sinonimi
(2S,4R)-1-((S)-2-(2-(2-(2-(4-(4-((3-Chloro-4-((3-fluorobenzyl)oxy)phenyl)amino)quinazolin-6- yl)phenoxy)ethoxy)ethoxy)acetamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide
Specifiche e purezza
≥98%(HPLC)
Meccanismi biochimici e fisiologici
Potent EGFR Degrader (DC50values are 39.2 nM for wild-type EGFR in OVCAR8 cells and 736 nM for Exon20Ins mutated EGFR in HeLa cells). Also degrades HER2. Comprises the EGFR inhibitorlapatinib joined by a linker to a von Hippel-Lindau (VHL) recruiting ligand. Inhibits proliferation of HER2-driven breast cancer cell lines (IC50= 102 nM for SKBr3 cells).
Condizioni di conservazione di stoccaggio
Store at -20°C
Spedito in
Ice chest + Ice pads
Questo prodotto richiede spedizione a catena fredda. I servizi di terra e altri servizi economici non sono disponibili.
Purezza
≥98%(HPLC)
Nomi e identificatori
SMILES
CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)C3CC(CN3C(=O)C(C(C)(C)C)NC(=O)COCCOCCOC4=CC=C(C=C4)C5=CC6=C(C=C5)N=CN=C6NC7=CC(=C(C=C7)OCC8=CC(=CC=C8)F)Cl)O
IUPAC Name
(2S,4R)-1-[(2S)-2-[[2-[2-[2-[4-[4-[3-chloro-4-[(3-fluorophenyl)methoxy]anilino]quinazolin-6-yl]phenoxy]ethoxy]ethoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide
InChIKey
ZSCOIFSUFMYZEZ-YSWDPXALSA-N
InChI
1S/C55H57ClFN7O8S/c1-34-50(73-33-61-34)38-10-8-35(9-11-38)28-58-53(67)47-27-42(65)29-64(47)54(68)51(55(2,3)4)63-49(66)31-70-21-20-69-22-23-71-43-16-12-37(13-17-43)39-14-18-46-44(25-39)52(60-32-59-46)62-41-15-19-48(45(56)26-41)72-30-36-6-5-7-40(57)24-36/h5-19,24-26,32-33,42,47,51,65H,20-23,27-31H2,1-4H3,(H,58,67)(H,63,66)(H,59,60,62)/t42-,47+,51-/m1/s1
Isomeri SMILES
CC1=C(SC=N1)C2=CC=C(C=C2)CNC(=O)[C@@H]3C[C@H](CN3C(=O)[C@H](C(C)(C)C)NC(=O)COCCOCCOC4=CC=C(C=C4)C5=CC6=C(C=C5)N=CN=C6NC7=CC(=C(C=C7)OCC8=CC(=CC=C8)F)Cl)O
PubChem CID
135157151
Peso molecolare
1030.61

Dati avanzati

Struttura 3D
Modello di struttura chimica interattiva





Obiettivi associati (umani)
SK-BR-3 (5175 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Meccanismi d'azione
Certificati (CoA, COO, BSE/TSE e tabella di analisi)
C of A & Other Certificates(BSE/TSE, COO):
Analytical Chart:
Proprietà chimiche e fisiche
SolubilitàSolvent:DMSO, Max Conc. mg/mL: 103.06, Max Conc. mM: 100
Calcolatori di soluzioni
Recensioni

Recensioni dei clienti

Prodotti correlati

AEE788 (NVP-AEE788) - ≥97% , Vascular endothelial growth factor receptor 1 inhibitor, CAS No.497839-62-0
ZM 306416 - Moligand™, ≥98% , Inhibitor of epidermal growth factor receptor;Inhibitor of fms related receptor tyrosine kinase 1;Inhibitor of kinase insert domain receptor, CAS No.690206-97-4
SJF 1521 - ≥98%(HPLC) , CAS No.2230821-40-4
RAF265 (CHIR-265) - Moligand™, ≥98% , Vascular endothelial growth factor receptor 2 inhibitor, CAS No.927880-90-8
PD153035 - ≥98% , CAS No.153436-54-5
PF 6274484 - ≥98% (HPLC) , CAS No.1035638-91-5
Ki8751 - ≥98% , CAS No.228559-41-9
SU1498 - ≥98%(HPLC) , CAS No.168835-82-3
VEGFR2 Kinase Inhibitor I - Moligand™, ≥98%, (including isomers) , Inhibitor of kinase insert domain receptor, CAS No.15966-93-5
AV 412 - ≥98%(HPLC) , CAS No.451492-95-8
AAL 993 - ≥98% , CAS No.269390-77-4
BMS 605541 - ≥98%(HPLC) , CAS No.639858-32-5
HKI 357 - ≥98%(HPLC) , CAS No.848133-17-5
KRN-633 - Moligand™, ≥97% , Vascular endothelial growth factor receptor inhibitor, CAS No.286370-15-8
PD168393 - ≥98% , CAS No.194423-15-9
AG 99 - ≥99%(HPLC) , CAS No.122520-85-8
PD 174265 - Moligand™, ≥98% , Inhibitor of epidermal growth factor receptor, CAS No.216163-53-0
VEGFR2 kinase inhibitor IV - Moligand™, ≥95% , Inhibitor of kinase insert domain receptor, CAS No.216661-57-3
Tyrphostin 47 - ≥99% , CAS No.122520-86-9
Src/EGFR inhibitor, CAS No.131023-24-0
Brivanib (BMS-540215) - Moligand™, ≥98% , Vascular endothelial growth factor receptor inhibitor, CAS No.649735-46-6
Brivanib Alaninate (BMS-582664) - Moligand™, ≥95% , Vascular endothelial growth factor receptor inhibitor, CAS No.649735-63-7
CGP 52411 , CAS No.145915-58-8
CO-1686 (AVL-301) - Moligand™, ≥99% , Epidermal growth factor receptor erbB1 inhibitor, CAS No.1374640-70-6
CUDC-101 - Moligand™, ≥98% , Histone deacetylase inhibitor, CAS No.1012054-59-9
EGFR inhibitor - Moligand™, ≥98% , Inhibitor of epidermal growth factor receptor, CAS No.879127-07-8
EGFR-IN-5 - ≥98% , CAS No.2225887-26-1
EGFR-IN-7 - ≥98% , CAS No.2267329-76-8
EGFR/ErbB-2/ErbB-4 inhibitor-2 - Moligand™, ≥98% , Inhibitor of epidermal growth factor receptor;Inhibitor of erb-b2 receptor tyrosine kinase 2, CAS No.179248-61-4
EGFR inhibitor - Moligand™, 10mM in DMSO , Inhibitor of epidermal growth factor receptor, CAS No.879127-07-8
JBJ-03-142-02 - ≥98%(HPLC) , CAS No.2068806-31-3
Ramucirumab (anti-VEGFR2) - Anticorpo primario, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to VEGFR2, >95%, Human IgG1, Antibody of kinase insert domain receptor
SU4312 - Moligand™, ≥98% , Inhibitor of kinase insert domain receptor, CAS No.5812-07-7
UNC0064-12 (VEGFR-2-IN-5) - ≥98% , CAS No.1430089-64-7
VEGFR Tyrosine Kinase Inhibitor II - Moligand™, ≥98% , Inhibitor of kinase insert domain receptor, CAS No.269390-69-4
VEGFR2 Kinase Inhibitor I - Moligand™, 10mM in DMSO , Inhibitor of kinase insert domain receptor, CAS No.15966-93-5
Panitumumab (anti-EGFR) - Anticorpo primario, for Flow,ELISA,Functional Assay,Kinetics (BLI),Kinetics (SPR) various applications, specific to EGFR, >95%, Human IgG2SA, Antibody of epidermal growth factor receptor
Cetuximab (anti-EGFR) - Anticorpo primario, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to ERBB1/EGFR/HER1, >95%, Human IgG1, Antibody of epidermal growth factor receptor
Necitumumab (anti-EGFR) - Anticorpo primario, for ELISA,Functional Assay,Flow cytometry,Kinetics (BLI),Kinetics (SPR) various applications, specific to EGFR, >95%, Human IgG1, Antibody of epidermal growth factor receptor
EGFR inhibitor 57 - Moligand™ , Allosteric modulator of epidermal growth factor receptor, CAS No.E610080
Nimotuzumab (anti-EGFR) - Anticorpo primario, specific to EGFR, >95%, Human IgG1, INHIBITOR of Epidermal growth factor receptor erbB1 inhibitor
EGFR Mouse mAb - Anticorpo primario, specific to EGFR, IgG2b

Desidera che le inviamo un messaggio quando avremo sconti disponibili?

Ricordamelo più tardi

Grazie! Controlli la sua casella di posta per confermare.

Ops! Le notifiche sono disabilitate.